Business Context and Reporting Period
This Form 8-K Current Report from NanoViricides, Inc. covers events occurring on January 23, 2016, specifically the Company's 2015 Annual Meeting of Stockholders. The filing details the election of directors, the ratification of the independent auditor, and a material amendment to the rights of Series A Convertible Preferred Shareholders.
Key Financial Metrics
This filing is a corporate governance report and does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. No financial statements are included in this document.
Material Changes and Corporate Actions
- Director Elections: Stockholders re-elected Anil Diwan, PhD, Dr. Milton Boniuk, and Mukund Kulkarni as Class I Directors for two-year terms expiring in 2017.
- Auditor Ratification: Stockholders ratified the appointment of Eisner Amper, LLP as the independent registered public accounting firm for the fiscal year ending June 30, 2016.
- Preferred Stock Amendment: The Board and a majority of Series A Convertible Preferred Shareholders approved an amendment to increase the authorized number of Series A Shares from 4,000,000 to 8,500,000.
Voting Results and Participation
Approximately 86.3% of the Company's outstanding voting capital stock was present or represented by proxy at the meeting.
| Proposal | Votes For | Votes Against | Votes Withheld | Percentage For |
|---|---|---|---|---|
| Re-election of Anil Diwan, PhD | 19,666,888 | 0 | 925,100 | 95.51% |
| Re-election of Dr. Milton Boniuk | 19,651,257 | 0 | 940,731 | 95.43% |
| Re-election of Mukund Kulkarni | 19,637,691 | 0 | 954,297 | 95.37% |
| Ratification of Eisner Amper, LLP | 45,142,927 | 1,886,477 | 1,779,347 | 92.48% |
Note: Voting results exclude Series A Preferred Shares, which vote at a rate of 9 votes per share. All 3,943,435 Series A shares voted in favor of the director elections and auditor ratification.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, or discussion of risks and contingencies. It strictly reports on the outcomes of the stockholder vote and the amendment to the Certificate of Designation for Series A Shares.
Key Facts for Investor Verification
- Verify the impact of increasing authorized Series A Convertible Preferred Shares from 4,000,000 to 8,500,000 on potential future dilution.
- Confirm the terms of the Series A Preferred Shares, specifically the 9-to-1 voting ratio relative to common stock.
- Review the Company's Proxy Statement filed on December 8, 2015, for detailed biographies of the re-elected directors and further context on the auditor appointment.
- Note that this filing does not contain financial results; refer to the most recent 10-K or 10-Q for financial health metrics.